Biotinylated Human VEGF165 Protein, epitope tag free, ultra sensitivity (primary amine labeling) (MALS verified)

ユーザーレビュー
製品番号/仕様
価格
数量
VE5-H8210-25ug
$300.00
VE5-H8210-200ug
$1295.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF

  • Source

    Biotinylated Human VEGF165, epitope tag free, primary amine labeling (VE5-H8210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4). In the region Ala 27 - Arg 191, the amino acid sequences of VEGF165 from Human, Cynomolgus and Rhesus macaque are identical. It is the biotinylated form of Human VEGF165, premium grade (Cat. No. VE5-H4210).

    Predicted N-terminus: Ala 27

    Request for sequence

  • Molecular Characterization

    VEGF165 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries no "tag".

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 25-28 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    The protein is designed as a dimer.

  • Labeling

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 24 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    VEGF165 SDS-PAGE

    Biotinylated Human VEGF165, epitope tag free, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    VEGF165 SEC-MALS

    The purity of Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) is more than 95% and the molecular weight of this protein is around 45-62 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     VEGF165 ELISA

    Immobilized Human VEGF R1 Protein, Fc Tag (Cat. No. VE1-H5253) at 1 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.02-1 ng/mL (QC tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Anti-VEGF MAb, Human IgG1 (Avastin) at 1 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.03-1 ng/mL (Routinely tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Human Neuropilin-1, His Tag (Cat. No. NR1-H5228) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.005-0.625 μg/mL (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Vascular endothelial growth factor A

  • カテゴリ:

  • 市販の医薬品数:

    54 詳細

  • 治験医薬品数:

    61 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8